G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024GlobeNewsWire • Thursday
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025InvestorPlace • 07/15/24
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)GlobeNewsWire • 06/24/24
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/05/24
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)GlobeNewsWire • 05/28/24
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingGlobeNewsWire • 05/23/24
G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation SummitGlobeNewsWire • 05/22/24
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesGlobeNewsWire • 05/22/24
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsGlobeNewsWire • 05/01/24
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibGlobeNewsWire • 05/01/24
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024GlobeNewsWire • 04/17/24
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/04/24
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsGlobeNewsWire • 02/28/24